NTRA
Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$399.42
+1.52%Year over year
Reported trailing growth
- Revenue
- +37.8%
- EBITDA
- +15.6%
- EBIT
- +1.3%
- EPS
- +28.8%
- Free cash flow
- -31.4%
- Operating cash flow
- +22.2%
Forward estimates
Based on analyst estimates
- Revenue
- +21.9%
- EBITDA
- +113.6%
- EPS
- +57.2%
Three-year CAGR
- Revenue
- +41.1%
- EBITDA
- -48.9%
- EBIT
- -39.4%
- Net income
- -9.3%
- EPS
- +0.7%
- Free cash flow
- +57.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026